ABSTRACT
INTRODUCTION
Cell-free (cf) DNA analysis of maternal blood provides effective screening for fetal trisomies 21, 18 and 13 with reported detection rates (DR) of 99%, 96% and 91%, respectively, at an overall false-positive rate (FPR) of 0.35% 1 . However, the test fails to provide a result in up to 8% of cases and the most common reason for such failure is low fetal fraction 2 . There are some limited data indicating that, in the pregnancies with failed results, fetal chromosomal abnormalities are over-represented 2 and this has led to a recommendation by the American College of Obstetricians and Gynecologists (ACOG) that, in cases of a failed result, women should be offered diagnostic testing 3 .
The objectives of this cohort study of 10 698 singleton pregnancies undergoing screening for fetal trisomies 21, 18 and 13 by cfDNA testing at 10-14 weeks' gestation were first, to report the distribution of fetal fraction of cfDNA and the rate of a failed result in each of the trisomies and compare with pregnancies unaffected by these trisomies, second, to examine the possible effects of maternal and fetal characteristics on the fetal fraction and third, to consider the options for the further management of pregnancies with a failed cfDNA test result. testing in women with singleton pregnancies attending for routine care at 11 + 0 to 13 + 6 weeks' gestation in one of two National Health Service (NHS) hospitals in England 4 and second, cfDNA testing as part of routine screening in women with singleton pregnancies at 10 + 0 to 13 + 6 weeks attending the Fetal Medicine Centre in London, which is a private clinic 5 . The patients were examined between October 2012 and August 2015.
We recorded maternal characteristics and medical history, including maternal age, racial origin (Caucasian, African, South Asian, East Asian and mixed), method of conception (natural/assisted conception requiring the use of ovulation drugs/in-vitro fertilization), cigarette smoking during pregnancy (yes/no) and parity (parous/nulliparous if no previous pregnancy at or after 24 weeks' gestation). We also measured maternal weight and height. In all cases, free beta-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) were measured within 10 min of blood collection at 10 + 0 to 13+ 6 weeks (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA, or Kryptor, Thermo Scientific, Berlin, Germany). An ultrasound scan was carried out at 11 + 0 to 13 + 6 weeks to determine gestational age from the measurement of the fetal crown-rump length (CRL) 6 , diagnose any major fetal abnormalities and measure fetal nuchal translucency (NT) thickness. The measured NT was expressed as a difference from the expected normal mean for gestation (delta value) 7 . Similarly, the measured free β-hCG and PAPP-A were converted into multiples of the median (MoM) for gestational age, adjusted for maternal weight, racial origin, smoking status, method of conception, parity and machine used for the assays 8 . Biophysical and biochemical markers were combined to estimate the patient-specific risk for trisomies 21, 18 and 13.
Women provided written informed consent and maternal blood (20 mL) was sent via courier to the USA for cfDNA testing (Harmony TM Prenatal Test, Ariosa Diagnostics, Inc., San Jose, CA, USA) 9 -13 . Chromosome-selective sequencing, referred to as digital analysis of selected regions (DANSR), and fetal-fraction optimized risk of trisomy evaluation (FORTE™) were used to assay non-polymorphic and polymorphic loci, where fetal alleles differ from maternal alleles, enabling simultaneous determination of chromosome proportion and fetal fraction. The results from cfDNA testing were presented as risk scores for trisomy 21, 18 and 13 which in most cases were either > 99% or < 1:10 000. In cases for which the cfDNA test did not provide results the parents were offered repeat testing or to rely on the results of the combined test in deciding whether to have an invasive test or not. In cases with a high-risk result from the cfDNA test, the parents were advised to consider having invasive fetal karyotyping before deciding on the further management of their pregnancy.
Patient characteristics and results of the investigations were recorded in a fetal database. Results from invasive testing, obtained from laboratories, and pregnancy outcome, obtained from obstetricians, general practitioners or the patients, were recorded in the same database. The outcomes were divided into first, trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood demonstrated the relevant trisomy, second, no trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood was normal or the neonate was phenotypically normal, third, unknown karyotype because the pregnancy resulted in miscarriage or stillbirth and no karyotyping of fetal tissue was carried out, and fourth, outcome unknown because the pregnancy was lost to follow up.
Statistical analysis
Descriptive data are presented as median and interquartile range (IQR) for continuous variables and as numbers and percentages for categorical variables. The measured fetal fraction was log 10 transformed to make the distribution Gaussian, which was assessed using histograms and probability plots. Univariate and multivariate regression analyses were used to determine which of the factors amongst maternal age, body mass index, racial origin, smoking status, method of conception, fetal CRL, serum PAPP-A and free β-hCG, fetal NT and fetal karyotype were significant predictors of log 10 fetal fraction. In each trisomic and unaffected pregnancy the log 10 fetal fraction was expressed as a MoM after adjusting for the maternal variables found to be significant in the multivariate regression analysis. Logistic regression analysis was undertaken to examine the maternal and pregnancy characteristics providing significant contribution to prediction of a failed cfDNA test result.
The statistical software package SPSS 21.0 (SPSS Inc., Chicago, IL, USA) was used for data analyses.
RESULTS

Characteristics of study population
A total of 10 963 women had cfDNA testing and combined screening for trisomies, but 265 (2.4%) of these were excluded from further analysis either because the pregnancy ended in termination, miscarriage or stillbirth with no known karyotype (n = 155), was lost to follow up (n = 85) or had a chromosomal abnormality other than trisomy 21, 18 or 13 (n = 25).
Maternal and pregnancy characteristics in the 10 698 cases with known outcome are summarized in Table 1 . There were 160 cases of trisomy 21, 50 of trisomy 18, 16 of trisomy 13 and 10 472 were unaffected by these trisomies. Results from cfDNA testing were provided after first sampling for 97.0% (10 382/10 698) of cases, including 97.1% in the unaffected group, 98.1% in trisomy 21, 92.0% in trisomy 18 and 93.7% in trisomy 13. The reasons for failure to provide a result were low fetal fraction in 219 (69.3%) cases and laboratory processing problems in 97 (30.7%) cases. Data are given as median (interquartile range) or n (%).
Factors affecting fetal fraction
At first sampling, the median fetal fraction was 11.0% (IQR, 8.3-14.4%) in the unaffected group, 10.7% (IQR, 7.8-14.3%) in trisomy 21, 8.6% (IQR, 5.0-10.2%) in trisomy 18 and 7.0% (IQR, 6.0-9.4%) in trisomy 13; in these calculations, it was assumed that in the cases with a failed result because of low fetal fraction, the fetal fraction was 3%. Log 10 fetal fraction from first sampling had a Gaussian distribution ( Figure 1 ). Univariate regression analysis demonstrated that significant independent prediction of log 10 fetal fraction was provided by maternal age, body mass index, African, South Asian and East Asian racial origins, assisted conception, MoM values of PAPP-A and free β-hCG and trisomies 18 and 13 ( Table 2 ). In the multivariate regression analysis, significant contribution was provided by maternal age, body mass index, South Asian racial origin, assisted conception, fetal CRL and MoM values of PAPP-A and free β-hCG, but not trisomies 18 or 13 (adjusted R 2 = 0.251; P < 0.0001). If in the multivariate regression analysis we excluded PAPP-A and free β-hCG MoM, significant contribution to log 10 fetal fraction was provided by maternal age, body mass index, South Asian racial origin, assisted conception, fetal CRL and trisomies 18 and 13 (adjusted R 2 = 0.174; P < 0.0001).
We used the coefficients of the maternal characteristics with significant contribution to log 10 fetal fraction in the multivariate regression analysis to derive a model for calculation of MoMs. The median fetal fraction MoM in unaffected pregnancies was 1.03 (IQR, 0.79-1.32). Multivariate logistic regression analysis demonstrated that the risk of test failure increased with increasing maternal age and body mass index, decreased with increasing PAPP-A and free β-hCG MoM and was higher in women of South Asian than Caucasian racial origin and in pregnancies achieved by assisted conception than those achieved naturally (adjusted R 2 = 0.212; P < 0.0001).
Management of pregnancies with cfDNA test failure
There was a failed cfDNA result after first sampling in 2.9% (308/10 472) of cases in the unaffected group, in 1.9% (3/160) with trisomy 21, 8.0% (4/50) with trisomy 18 and 6.3% (1/16) with trisomy 13 (Table 3) .
In the 308 unaffected cases with a failed cfDNA result, 234 (76.0%) chose repeat cfDNA testing, eight (2.6%) had invasive testing and 66 (21.4%) opted for no further investigations. Repeat cfDNA testing provided a result in 147 (62.8%) of the 234 cases; seven (8.0%) of the 87 with a failed second cfDNA test had invasive testing and 80 (92.0%) opted for no further investigations. In total, 15 (4.9%) of the 308 women with a failed cfDNA result ended up having an invasive test and in 13 (86.7%) of the 15 cases in this group the estimated risk for trisomies from the combined test was ≥ 1 in 100. In contrast, in the 146 cases with no result from first or repeat cfDNA testing and who decided against invasive testing, only 14 (9.6%) had an estimated risk for trisomies from the combined test of ≥ 1 in 100.
In two of the three cases of trisomy 21 with a failed cfDNA result, invasive testing was carried out because the estimated risk from the combined test was ≥ 1 in 3; Table 2 . Comparison with normal pregnancy: *P < 0.05.
in the third case, with an estimated risk of 1 in 13, the cfDNA test was repeated and this gave a result. In the four cases of trisomy 18 with a failed cfDNA result, invasive testing was carried out because in all cases the estimated risk from the combined test was ≥ 1 in 5, serum PAPP-A and free β-hCG was ≤ 0.3 MoM and there were sonographic features suggestive of this trisomy, including clenched hands, cardiac defect and/or exomphalos. In the case of trisomy 13 with a failed cfDNA test result, invasive testing was carried out because the estimated risk from the combined test was 1 in 2, the fetal NT was 4.1 mm and the fetal heart rate was 200 bpm.
DISCUSSION
Principal findings of the study
In this study, selective sequencing was used for cfDNA analysis of maternal blood in screening for fetal trisomies 21, 18 and 13 at 10-14 weeks' gestation. The median fetal Values are given as n, median (interquartile range) or n/N (%). MoM, multiples of the median.
fraction was 11.0% and this decreased with increasing maternal age and body mass index, increased with fetal CRL and maternal serum free β-hCG and PAPP-A MoM and was lower in women of South Asian racial origin than in Caucasians and in pregnancies conceived by assisted reproduction techniques than in natural conceptions.
The median fetal fraction in pregnancies with fetal trisomy 21 was not significantly different from that in unaffected pregnancies. In trisomies 18 and 13, the fetal fraction was significantly reduced and this decrease could be explained by the association of these trisomies with low serum PAPP-A and free β-hCG, reflecting the smaller placental source of fetal cfDNA in maternal blood.
In 3% of pregnancies the cfDNA test failed to provide a result after first sampling and the main reason for such failure was low fetal fraction of < 4%. The rate of a failed result was similar in unaffected and trisomy-21 cases, but was increased in trisomy 18 and 13 pregnancies. Logistic regression analysis demonstrated that the risk of a failed cfDNA test was inevitably affected by the same factors as those affecting fetal fraction. Thus, the rate of a failed result increased with increasing maternal age and body mass index, decreased with increasing maternal serum level of free β-hCG and PAPP-A MoM and was higher in women of South Asian racial origin than in Caucasians and in pregnancies conceived by assisted reproduction techniques than in natural conceptions.
The options for the management of pregnancies with a failed cfDNA test result after first sampling include repeat cfDNA testing, invasive testing or no further investigation; similarly, the options for women with a second failed cfDNA test are invasive testing or no further investigation. An important determinant for selecting the appropriate management option is the estimated risk for trisomies from the combined test and the presence of sonographic features suggestive of trisomies 18 and 13. In this study, only 7% (22/316) with a failed cfDNA test chose to have invasive testing and in 91% of these cases the estimated risk for trisomies from the combined test was ≥ 1 in 100. In contrast, in the patients with a failed cfDNA test, after either first or repeat testing, who decided against invasive testing, only 13% had an estimated risk for trisomies from the combined test of ≥ 1 in 100.
Comparison of findings to those in previous studies
The inverse association between fetal fraction and maternal body mass index, which could be attributed to a dilutional effect, but also an increase in maternal cfDNA with increasing weight, is compatible with the results of previous cfDNA studies 12 -15 . Similarly, our finding of a linear association between fetal fraction and serum free β-hCG and PAPP-A MoM provides further support to our suggestion that, since all three are produced by the placenta, their maternal serum levels provide an indirect measure of placental mass 12 -14 . A three-dimensional ultrasound study reported that, in trisomy-21 pregnancies, placental volume at 11-13 weeks' gestation was not significantly different from that in euploid pregnancies, but in trisomies 18 and 13 placental volume was decreased 16 . In previous studies we found that the fetal fraction is decreased in women of African racial origin, primarily because of an increase in maternal cfDNA level rather than a decrease in fetal cfDNA in maternal blood 12 -14 . In this larger study, we found in the univariate analysis that, in women of African racial origin, the fetal fraction was significantly lower than in Caucasians but in the multivariate analysis this significance was lost. In contrast, in women of South Asian racial origin, the fetal fraction was significantly reduced both in the univariate and multivariate analyses and this decrease may be a consequence of an increase in maternal cfDNA level, rather than a decrease in fetal cfDNA in maternal blood 14 . The finding that, in pregnancies conceived by assisted reproduction techniques, the fetal fraction is lower than in natural conceptions is compatible with a previous report in multiple pregnancies 17 and this may be the consequence of the degree of impaired placentation which can also explain the higher incidence of associated pregnancy complications, such as pre-eclampsia 18 .
A few studies compared fetal fraction in pregnancies with fetal trisomies 21, 18 or 13 with that in euploid pregnancies. Rava et al. examined high-risk pregnancies undergoing invasive testing at 10-23 weeks' gestation, including 160 euploid pregnancies and 90, 38 and 16 with trisomies 21, 18 and 13, respectively 19 . The mean fetal fraction was significantly higher in trisomy 21 (13.5%) than in euploid pregnancies (12.6%) and was significantly lower in trisomies 18 (8.9%) and 13 (9.0%) than in euploid pregnancies (12.6%). Dar 21 . The median fetal fraction in trisomy 21 (15.5%) was higher and in trisomy 18 (9.4%) was lower than in euploid pregnancies (13.3%); the value in trisomy 13 was 13.6%. Kinnings et al. reported the results of screening at a median gestational age of 13 (range, 10-40) weeks in 140 377 pregnancies, including 2214 with trisomy 21, 835 with trisomy 18 and 432 with trisomy 13 22 . The median fetal fraction increased with gestational age, decreased with maternal weight and was affected by the fetal aneuploidy status; the median value was 9.6% for euploid and trisomy 21 pregnancies, 8.2% for trisomy 18 and 8.7% for trisomy 13 . The study also demonstrated that the fetal fraction in trisomic, compared to euploid pregnancies, changed with gestational age; the fetal fraction was initially lower for all three trisomies but then became higher than in euploid pregnancies after 16, 21 and 18 weeks for trisomies 21, 18 and 13, respectively 22 .
Implications for clinical practice
On the basis of the results from this and previous studies, it can be concluded that, in trisomies 18 and 13, but not in trisomy 21, the fetal fraction is lower and the rate of failed cfDNA test is higher than in unaffected pregnancies. Consequently, pregnancies with a failed test can be considered as being at increased risk for trisomies 18 and 13, but not for trisomy 21. However, the results of the study of Kinnings et al. suggest that this problem of over-representation of trisomies 18 and 13 in pregnancies with a failed cfDNA test is confined to the first half of pregnancy 22 .
The management of pregnancies with a failed cfDNA test should depend essentially on the reason for carrying out such a test in the first place, as well as the cost of the cfDNA test; however, most companies will repeat the test at no additional cost. If there was prior screening with a low-risk result, the preferred option would be to repeat the cfDNA test and explain to the parents that such testing would provide a result in > 60% of cases. Some patients would prefer to avoid any further testing because of the associated anxiety; in these patients and in those with a failed second cfDNA test it would be advisable to carry out a detailed ultrasound scan for features of trisomies 18 and 13 and in the presence of such features invasive testing should be considered. If prior screening had provided a high-risk result but there are no ultrasound features of aneuploidy, most patients would prefer repeat cfDNA testing but a few would select to have invasive testing.
Conclusions
In cases of failed cfDNA test, fetal trisomies 18 and 13, but not trisomy 21, are over-represented. In the management of such cases, the decision in favor of invasive testing should depend on the risk from prior screening and the results of detailed ultrasound examination.
RESUMEN
Objetivos Primero, informar sobre la distribución de la fracción de ADN fetal en sangre materna (cfDNA, por sus siglas en inglés) y la tasa del resultado de una prueba fallida de cfDNA en las trisomías 21, 18 y 13, en comparación con embarazos no afectados por estas trisomías; segundo, examinar los posibles efectos de las características maternas y fetales en la fracción fetal; y tercero, considerar las opciones para el manejo posterior de los embarazos con un resultado fallido.
MétodosÉste fue un estudio de cohorte de 10 698 embarazosúnicos sometidos a un cribado para las trisomías fetales 21, 18 y 13 mediante la prueba de cfDNA a las 10-14 semanas de gestación. Se obtuvieron 160 casos con trisomía 21, 50 con trisomía 18, 16 con trisomía 13 y 10 472 no se vieron afectados por estas trisomías. Se utilizó un análisis de regresión multivariante para determinar los predictores significativos de la fracción fetal y del resultado fallido de la prueba de cfDNA a partir de características maternas y fetales.
Resultados La fracción fetal disminuyó con el aumento delíndice de masa corporal y la edad materna, fue menor en las mujeres con etnicidad del sur de Asia que en las caucásicas y en las fecundaciones asistidas, en comparación con las espontáneas. La fracción fetal aumentó con la longitud céfalo-caudal (coronilla-rabadilla) del feto y con mayores niveles en el suero de la proteína plasmática A asociada al embarazo y la hormona gonadotrópica corioniónica humana (subunidad B). La mediana de la fracción fetal fue del 11,0% (rango intercuartílico (RIC), 8,3-14,4%) en el grupo no afectado, del 10,7% (RIC, 7,8-14,3%) en la trisomía 21, del 8,6% (RIC, 5,0-10,2%) en la trisomía 18 y del 7.0% (RIC, 6,0-9,4%) en la trisomía 13. Se encontró un resultado fallido de la prueba de cfDNA después de la primera toma de muestras en el 2,9% del grupo no afecto, el 1,9% de la trisomía 21, el 8,0% de la trisomía 18 y el 6.3% de la trisomía 13. En los casos con resultado fallido, el 7% de las mujeres tuvieron pruebas invasivas, principalmente debido al riesgo elevado de la prueba combinada y/o la presencia de características ecográficas que sugerían trisomías 18 y 13. Todos los casos de trisomías se detectaron prenatalmente.
Conclusiones En los casos de una prueba de cfDNA fallida, la tasa de las trisomías 18 y 13, pero no la de la trisomía 21, es mayor que en aquellos con una prueba exitosa. En el manejo de estos casos, la decisión a favor de las pruebas invasivas debería depender del riesgo de cribado previo y los resultados de un examen ecográfico detallado.
